Product Description
Medicine Details
- Brand Name: Erlocip 150mg
- Generic Name: Erlotinib Tablets
- Contents: Erlotinib 150mg
- Form: Tablets
- Manufacturer Cipla India Ltd
- Packing: Pack of 30 tabs
1. Erlocip is consumed for curing non-small cell lung cancer.
2. Erlocip is consumed in blend with gemcitabine for curing pancreatic cancer that has spread to nearby tissues or to other parts of the body.
Mechanism of Action
Erlocip works by controlling the activity of an abnormal protein that lowers the growth of cancer cells. This supports minimize or stop the spread of cancer cells.
Effective EGFR Inhibition for OncologyErlocip harnesses the precision of EGFR inhibition, demonstrating proven efficacy in treating certain advanced cancers. The targeted action against the Epidermal Growth Factor Receptor disrupts cancer cell signaling, offering hope for improved clinical outcomes in adults diagnosed with non-small cell lung or pancreatic cancer. Physicians rely on Erlocip for its high purity and stable formulation.
Simple Oral Administration for Patient ConvenienceErlocip comes in easy-to-administer tablet form, supporting ongoing cancer management. Adults prescribed this therapy ingest the medication orally as directed by their oncologist. This route ensures direct delivery, aiding compliance and ease of use. Packaging by strips or boxes enables secure handling and optimal freshness throughout its shelf life.
Maintain Safety Through Medical SupervisionAs a prescription-only anticancer therapy, Erlocip requires careful oversight. Potential interactions, contraindications, and individual health profiles must be reviewed by physicians before initiating treatment. Adhering to storage guidelines, monitoring for hypersensitivity, and observing expiry details are critical for maximizing therapeutic benefit and minimizing risks.
FAQs of Erlocip Medicines:
Q: How should Erlocip tablets be administered for optimal effectiveness?
A: Erlocip tablets are taken orally, exactly as prescribed by your healthcare provider. Swallow the tablet whole with water, without crushing or splitting, and follow the dosing schedule recommended for your type of cancer.
Q: What types of cancer are commonly treated with Erlocip?
A: Erlocip is indicated for adults with non-small cell lung cancer and pancreatic cancer, where its ability to inhibit the EGFR pathway helps slow tumor growth and proliferation.
Q: When should Erlocip not be used, and who is contraindicated?
A: Erlocip should not be used by individuals with known hypersensitivity to Erlotinib hydrochloride or any component of the tablet. Always disclose your allergies to your healthcare provider prior to use.
Q: Where should Erlocip be stored to maintain quality and safety?
A: Store Erlocip tablets below 30C, in their original packaging, protected from light and moisture. Proper storage preserves the drugs efficacy for up to 24 months as per the expiry date on the pack.
Q: What are the key benefits of Erlocip in oncology settings?
A: Erlocip offers high purity, stable formulation, and potent EGFR inhibition, contributing to effective and targeted therapy in cancer management under specialist supervision.
Q: Does Erlocip interact with other medications, and what should be considered?
A: Yes, Erlocip may interact with CYP3A4 inhibitors or inducers, potentially affecting its metabolism or efficacy. Inform your doctor of all medicines and supplements you are taking before starting Erlocip.
Q: What process ensures Erlocips quality and safety for patient use?
A: Erlocip is GMP certified, manufactured under stringent pharmaceutical standards. Each batch undergoes rigorous testing for purity, potency, and formulation stability to guarantee safety for patient use.